High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 8 High-frequency irreversible electroporation combined with BMS-1 and R848 elicits systemic antitumor immunity by modulating splenic immune cell subsets. A and B: Proportion of splenic CD3+ CD4+ T cells; C and D: Proportion of splenic CD3+ CD8+ T cells; E and F: Proportion of splenic CD4+ CD25+ FOXP3+ Tregs; G and H: Proportion of splenic CD11c+ CD80+ CD86+ dendritic cells; I-L: Polarization of splenic macrophages: Proportion of F4/80+ CD11b+ CD86+ M1 and F4/80+ CD11b+ CD206+ M2 macrophages and the M1/M2 macrophage ratio. Each panel shows representative flow cytometry plots alongside quantitative data (n = 5). ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001. H-FIRE: High-frequency irreversible electroporation.